Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$43.53-1.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · SUPN
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 8 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $44 the market pays 21× p/e — above the 16× p/e peer median but in line with its own 19× history. That premium reflects a durable franchise our peer-anchored $32 fair value understates; treat the 'expensive vs peers' read with medium confidence. Even valued only for durable growth at sustainable margins, it's worth about $76 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcff | 12M | $4.72 | — | — | Hist. CAGR | high |
| graham number | 12M | $28.91 | — | — | TTM | high |
| Peer P/FCF | 12M | $4.57 | 14.1 | 0.32 | TTM | high |
| Peer P/E | 12M | $33.62 | 16.1 | 2.09 | TTM | high |
| Peer P/S | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $41.55 |
| 2.9 |
| 14.30 |
| TTM |
| high |
| residual income | 12M | $20.52 | — | — | TTM | high |
| Own P/E history | 12M | $38.93 | 18.6 | 2.09 | TTM | high |
| triangulated | 12M | $37.27 | 16.1 | 2.32 | Triangulated | high |
| Peer P/E | 3Y | $75.42 | 16.1 | 4.69 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $72.22 | 2.9 | 24.86 | guidance | medium |
| Own P/E history | 3Y | $87.33 | 18.6 | 4.69 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $79.94 | 16.1 | 4.98 | Hist. CAGR(prov.) | high |
| Peer P/S | 5Y | $76.56 | 2.9 | 26.35 | guidance | high |
| Own P/E history | 5Y | $92.58 | 18.6 | 4.98 | Hist. CAGR(prov.) | high |